Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Brain Neoplasms 2Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1NSCLC 1Meningeal Carcinomatosis 1Liver Diseases 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-small Cell Lung Cancer Metastatic × aumolertinib × Thoracic × Clear all
NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Shanghai Cancer Hospital, China

Phase 3 Recruiting
300 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡